Syros Pharmaceuticals Stock Current Asset
| SYRS Stock | USD 5.61 0.16 2.94% |
Syros Pharmaceuticals fundamentals help investors to digest information that contributes to Syros Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Syros Stock. The fundamental analysis module provides a way to measure Syros Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Syros Pharmaceuticals stock.
Non Current Assets Total is likely to drop to about 21.7 M in 2024. Other Current Assets is likely to drop to about 2.8 M in 2024. Syros | Current Asset |
Syros Pharmaceuticals Company Current Asset Analysis
Syros Pharmaceuticals' Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Current Syros Pharmaceuticals Current Asset | 85.51 M |
Most of Syros Pharmaceuticals' fundamental indicators, such as Current Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Syros Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Syros Current Asset Historical Pattern
Today, most investors in Syros Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Syros Pharmaceuticals' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Syros Pharmaceuticals current asset as a starting point in their analysis.
Syros Pharmaceuticals Current Asset |
| Timeline |
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
| Competition |
Syros Total Assets
Total Assets |
|
In accordance with the recently published financial statements, Syros Pharmaceuticals has a Current Asset of 85.51 M. This is 96.03% lower than that of the Biotechnology sector and 91.94% lower than that of the Health Care industry. The current asset for all United States stocks is 99.08% higher than that of the company.
Syros Current Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Syros Pharmaceuticals' direct or indirect competition against its Current Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Syros Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Syros Pharmaceuticals by comparing valuation metrics of similar companies.Syros Pharmaceuticals is currently under evaluation in current asset category among related companies.
Syros Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Syros Pharmaceuticals from analyzing Syros Pharmaceuticals' financial statements. These drivers represent accounts that assess Syros Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Syros Pharmaceuticals' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 277.9M | 499.7M | 203.9M | 45.3M | 220.7M | 153.7M | |
| Enterprise Value | 262.4M | 391.9M | 176.8M | (58.5M) | 143.2M | 108.2M |
Syros Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Syros Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Syros Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Syros Fundamentals
| Return On Equity | -2.37 | ||||
| Return On Asset | -0.46 | ||||
| Operating Margin | (17.79) % | ||||
| Current Valuation | 99.04 M | ||||
| Shares Outstanding | 26.73 M | ||||
| Shares Owned By Insiders | 1.32 % | ||||
| Shares Owned By Institutions | 84.94 % | ||||
| Number Of Shares Shorted | 1.45 M | ||||
| Price To Earning | (7.92) X | ||||
| Price To Book | 8.56 X | ||||
| Price To Sales | 14.35 X | ||||
| Revenue | 9.94 M | ||||
| Gross Profit | 14.88 M | ||||
| EBITDA | (124.25 M) | ||||
| Net Income | (164.57 M) | ||||
| Cash And Equivalents | 244.48 M | ||||
| Cash Per Share | 12.09 X | ||||
| Total Debt | 62.08 M | ||||
| Debt To Equity | 0.49 % | ||||
| Current Ratio | 6.57 X | ||||
| Book Value Per Share | 0.56 X | ||||
| Cash Flow From Operations | (109.77 M) | ||||
| Short Ratio | 6.12 X | ||||
| Earnings Per Share | (5.06) X | ||||
| Target Price | 19.25 | ||||
| Number Of Employees | 68 | ||||
| Beta | 1.75 | ||||
| Market Capitalization | 145.67 M | ||||
| Total Asset | 168.17 M | ||||
| Retained Earnings | (722.81 M) | ||||
| Working Capital | 108.3 M | ||||
| Current Asset | 85.51 M | ||||
| Current Liabilities | 9.57 M | ||||
| Net Asset | 168.17 M |
About Syros Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Syros Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Syros Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Syros Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Syros Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Syros Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Syros Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Syros Stock
| 0.75 | DVAX | Dynavax Technologies | PairCorr |
Moving against Syros Stock
| 0.58 | XFOR | X4 Pharmaceuticals | PairCorr |
| 0.45 | MRK | Merck Company Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to Syros Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Syros Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Syros Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Syros Pharmaceuticals to buy it.
The correlation of Syros Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Syros Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Syros Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Syros Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Syros Pharmaceuticals Piotroski F Score and Syros Pharmaceuticals Altman Z Score analysis. For more information on how to buy Syros Stock please use our How to Invest in Syros Pharmaceuticals guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Complementary Tools for Syros Stock analysis
When running Syros Pharmaceuticals' price analysis, check to measure Syros Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syros Pharmaceuticals is operating at the current time. Most of Syros Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syros Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syros Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syros Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |
Is Syros Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Syros Pharmaceuticals. If investors know Syros will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Syros Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.06) | Revenue Per Share 0.224 | Quarterly Revenue Growth (0.03) | Return On Assets (0.46) | Return On Equity (2.37) |
The market value of Syros Pharmaceuticals is measured differently than its book value, which is the value of Syros that is recorded on the company's balance sheet. Investors also form their own opinion of Syros Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Syros Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Syros Pharmaceuticals' market value can be influenced by many factors that don't directly affect Syros Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Syros Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Syros Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Syros Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.